Farrugia Rosienne, Scerri Christian A, Montalto Simon Attard, Parascandolo Raymond, Neville Brian G R, Felice Alex E
Laboratory of Molecular Genetics, Department of Physiology and Biochemistry, Faculty of Medicine and Surgery, University of Malta, Msida, Malta.
Mol Genet Metab. 2007 Mar;90(3):277-83. doi: 10.1016/j.ymgme.2006.10.013. Epub 2006 Dec 22.
Deficient activity of the Dihydropteridine Reductase enzyme (DHPR; EC 1.5.1.34; OMIM 261630) is due to mutations in the Quinoid Dihydropteridine Reductase gene on 4p15.3 (QDPR; RefSeq NM_000320). It results in defective recycling of tetrahydrobiopterin (BH(4)) and homozygotes have a rare form of atypical Hyperphenylalaninaemia and Phenylketonuria (aPKU). The heterozygote frequency in the Maltese population is high at 3.3%. The more recently described and rarer type of BH(4) deficiency due to Sepiapterin Reductase enzyme deficiency (SR; EC 1.1.1.153; OMIM 182125), which presents as an atypical form of Dopa Responsive Dystonia (DRD) [L. Bonafe, B. Thony, J.M. Penzien, B. Czarnecki, N. Blau, Mutations in the sepiapterin reductase gene cause a novel tetrahydrobiopterin-dependent monoamine-neurotransmitter deficiency without hyperphenylalaninemia, Am. J. Hum. Genet. 69 (2001) 269-277; B.R.G. Neville, R. Parascandalo, S. Attard Montalto, R. Farrugia, A.E. Felice, A congenital dopa responsive motor disorder: a Maltese variant due to sepiapterin reductase deficiency, Brain 128 (Pt10) (2005) 2291-2296.] has also been identified at high frequency (4.6%) in this population. Two mutations, the c.68G>A in QDPR (p.G23D), and the new SPR, IVS2-2A>G mutation at the splice site consensus sequence in intron 2 of the Sepiapterin Reductase gene (SPR; RefSeq NM_003124) on 2p14-p12, were found to be the sole causative mutations in all the patients with DHPR deficiency and SR deficiency studied. All parents were heterozygotes for the corresponding mutation and showed no clinical symptoms. Three polymorphisms, c.96C>T (p.A32A), c. 345G>A (p.S115S) and c. 396G>A (p.L132L), have also been identified in the QDPR gene, defining four wild-type frameworks, useful in molecular epidemiology studies. The c. 68G>A mutation in QDPR was found only on framework I, suggesting a founder effect. In contrast no additional sequence diversity was found in the SPR gene whether in wild-type or mutant alleles which is also consistent with a founder effect.
二氢蝶啶还原酶(DHPR;EC 1.5.1.34;OMIM 261630)活性不足是由于4p15.3上的醌型二氢蝶啶还原酶基因(QDPR;RefSeq NM_000320)发生突变所致。这导致四氢生物蝶呤(BH(4))循环利用存在缺陷,纯合子患有罕见的非典型高苯丙氨酸血症和苯丙酮尿症(aPKU)。马耳他人群中杂合子频率较高,为3.3%。最近描述的且较为罕见的因蝶呤还原酶缺乏(SR;EC 1.1.1.153;OMIM 182125)导致的BH(4)缺乏类型,表现为多巴反应性肌张力障碍(DRD)的非典型形式[L. 博纳费、B. 托尼、J.M. 彭齐恩、B. 恰尔内茨基、N. 布劳,蝶呤还原酶基因突变导致一种新型的依赖四氢生物蝶呤的单胺神经递质缺乏且无高苯丙氨酸血症,《美国人类遗传学杂志》69(2001年)269 - 277;B.R.G. 内维尔、R. 帕拉斯坎达洛、S. 阿塔尔德·蒙塔尔托、R. 法鲁吉亚、A.E. 费利切,一种先天性多巴反应性运动障碍:马耳他因蝶呤还原酶缺乏导致的变异型,《大脑》128(第10部分)(2005年)2291 - 2296。] 在该人群中也被高频发现(4.6%)。在所有研究的DHPR缺乏和SR缺乏患者中,发现两个突变,即QDPR中的c.68G>A(p.G23D),以及位于2p14 - p12上蝶呤还原酶基因(SPR;RefSeq NM_003124)内含子2剪接位点共有序列处的新的SPR IVS2 - 2A>G突变,是唯一的致病突变。所有父母均为相应突变的杂合子,且无临床症状。在QDPR基因中还鉴定出三个多态性位点,c.96C>T(p.A32A)、c. 当345G>A(p.S115S)和c. 396G>A(p.L132L),定义了四个野生型框架,对分子流行病学研究有用。QDPR中的c. 68G>A突变仅在框架I上被发现,提示存在奠基者效应。相比之下,在SPR基因中,无论是野生型还是突变等位基因,均未发现其他序列多样性,这也与奠基者效应一致。